| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Basic Science: Basic ScienceImaging - Peptides and Small Molecules |
1 Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
196
Objectives: The short half life of [11C]-Acetate has limited its use as a highly sensitive marker for prostate and other non FDG avid tumors. [18F]-Fluoroacetate has also been used for imaging prostate tumors but with limited success. Here in we present our results with [18F]-NP3-029 for imaging CWR22 prostate tumor xenografts (CWR22) in nude mice.
Methods: [18F]-NP3-029 was synthesized by using standard procedures using [18F]-KF/Kryptofix in acetonitrile at 80 0C, followed by HPLC purification and deprotection. The product was formulated in PBS (pH 7.4) and used for in vivo imaging studies. For the prostate tumor model, nude mice were implanted s.c. with 5 x 106 CWR22 cells and used two weeks later for imaging. [18F]-NP3-029 (7.4 MBq) was injected via tail vein and the mice were imaged using MicroPET. The mice were imaged the following day with [18F]-FDG for comparison.
Results: [18F]-NP3-029 was synthesized in excellent yields (>50% dc) and high purity (>98%). MicroPET imaging studies reveal that the compound is taken up in the tumor. Also high uptake was observed in brain and heart similar to [11C]-Acetate. Though the compound predominantly clears through urine, no uptake in kidneys was observed. Unlike [18F]-FDG, we were able to clearly visualize the tumors in MicroPET images.
Conclusions: MicroPET imaging studies indicate a high tumor to background ratio suggesting that [18F]-NP3-029 is a promising PET probe for imaging prostate tumors.
| ||||||||||||||||||||||||||||||||||||||
